Anti-Obesity Drugs Market Size, Trends, Growth, Forecast: By Drug Type: Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Others; By Drug Class; By Mechanism of Action; By Prescription Type; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Anti-Obesity Drugs Market Overview – 8 Major Markets 
    3.1    Anti-Obesity Drugs Market Historical Value (2017-2023) 
    3.2    Anti-Obesity Drugs Market Forecast Value (2024-2032) 
4    Obesity  Overview 
    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Anti-Obesity Drugs Epidemiology Scenario and Forecast – 8 Major Markets
    6.1    8MM Epidemiology Scenario Overview (2017-2032)
    6.2    United States Obesity   Epidemiology Scenario and Forecast (2017-2032)
    6.3    EU-4 and United Kingdom Obesity Epidemiology Scenario and Forecast (2017-2032)
        6.3.1    Germany Obesity Epidemiology Scenario and Forecast (2017-2032)
        6.3.2    France Obesity Epidemiology Scenario and Forecast (2017-2032)
        6.3.3    Italy Obesity Epidemiology Scenario and Forecast (2017-2032)
        6.3.4    Spain Obesity Epidemiology Scenario and Forecast (2017-2032)
        6.3.5    United Kingdom Obesity Epidemiology Scenario and Forecast (2017-2032)
    6.4    Japan Obesity Epidemiology Scenario and Forecast (2017-2032) 
    6.5    India Obesity Epidemiology Scenario and Forecast (2017-2032)
7    Anti-Obesity Drugs Market Landscape – 8 Major Markets 
    7.1    Anti-Obesity Drugs: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Anti-Obesity Drugs: Product Landscape
        7.2.1    Analysis by Prescription Type
        7.2.2    Analysis by Drug Type
        7.2.3     Analysis by Drug Class
        7.2.4    Analysis by Mechanism of Action
        7.2.5    Analysis by Route of Administration 
8    Anti-Obesity Drugs Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of  Treatment
10    Anti-Obesity  Drugs Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Anti-Obesity  Drugs Market Segmentation (2017-2032) - 8 Major Markets 
    11.1     Anti-Obesity Drugs Market (2017-2032) by Drug Type
        11.1.1    Market Overview
        11.1.2    Semaglutide 
        11.1.3    Phentermine/Topiramate 
        11.1.4    Naltrexone/Bupropion 
        11.1.5    Liraglutide 
        11.1.6    Gelesis 100 
        11.1.7    Orlistat 
        11.1.8    Phentermine 
        11.1.9    Methamphetamine 
        11.1.10    Tirzepatide  
        11.1.11    Others
    11.2    Anti-Obesity Drugs Market (2017-2032) by Drug Class
        11.2.1    Market Overview
        11.2.2    Amphetamine  
        11.2.3    GLP-1 Receptor Agonist
        11.2.4    Lipase Inhibitor
        11.2.5    Others  
    11.3    Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action 
        11.3.1    Market Overview
        11.3.2    Centrally Acting Drugs
        11.3.3    Peripherally Acting Drugs  
    11.4    Anti-Obesity Drugs Market (2017-2032) by Prescription Type 
        11.4.1    Market Overview
        11.4.2    Prescription Drugs 
        11.4.3    Over The Counter Drugs  
    11.5    Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital Pharmacies 
        11.5.3    Drug Store & Retail Pharmacies 
        11.5.4    Online Pharmacies 
    11.6    Anti-Obesity Drugs Market (2017-2032) by Region
        11.6.1    Market Overview
        11.6.2    United States
        11.6.3    EU-4 and the United Kingdom
            11.6.3.1    Germany
            11.6.3.2    France
            11.6.3.3    Italy
            11.6.3.4    Spain
            11.6.3.5    United Kingdom
        11.6.4    Japan
        11.6.5    India 
12    United States Anti-Obesity Drugs Market (2017-2032)
    12.1    United States Anti-Obesity Drugs Market Historical Value (2017-2023) 
    12.2    United States Anti-Obesity Drugs Market Forecast Value (2024-2032)
    12.3    United States Anti-Obesity Drugs Market (2017-2032) by Drug Type
        12.3.1    Market Overview
        12.3.2    Semaglutide 
        12.3.3    Phentermine/topiramate 
        12.3.4    Naltrexone/bupropion 
        12.3.5    Liraglutide 
        12.3.6    Gelesis 100 
        12.3.7    Orlistat 
        12.3.8    Phentermine 
        12.3.9    Methamphetamine 
        12.3.10    Tirzepatide    
    12.4    United States Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action 
        12.4.1    Market Overview
        12.4.2    Centrally Acting Drugs
        12.4.3    Peripherally Acting Drugs
13    EU-4 and United Kingdom Anti-Obesity Drugs Market (2017-2032)
    13.1    EU-4 and United Kingdom Anti-Obesity Drugs Market Historical Value (2017-2023) 
    13.2    EU-4 and United Kingdom Anti-Obesity Drugs Market Forecast Value (2024-2032)
    13.3    EU-4 and United Kingdom Anti-Obesity Drugs Market Overview
    13.4    EU-4 and United Kingdom Anti-Obesity Drugs Market (2017-2032) by Drug Type
        13.4.1    Market Overview
        13.4.2    Semaglutide 
        13.4.3    Phentermine/topiramate 
        13.4.4    Naltrexone/bupropion 
        13.4.5    Liraglutide 
        13.4.6    Gelesis 100 
        13.4.7    Orlistat 
        13.4.8    Phentermine 
        13.4.9    Methamphetamine 
        13.4.10    Tirzepatide  
    13.5    EU-4 and United Kingdom Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action 
        13.5.1    Market Overview
        13.5.2    Centrally Acting Drugs
        13.5.3    Peripherally Acting Drugs 
14    Japan Anti-Obesity Drugs Market
    14.1    Japan Anti-Obesity Drugs Market Historical Value (2017-2023) 
    14.2    Japan Anti-Obesity Drugs Market Forecast Value (2024-2032)
    14.3    Japan Anti-Obesity Drugs Market (2017-2032) by Drug Type
        14.3.1    Market Overview
        14.3.2    Semaglutide 
        14.3.3    Phentermine/topiramate 
        14.3.4    Naltrexone/bupropion 
        14.3.5    Liraglutide 
        14.3.6    Gelesis 100 
        14.3.7    Orlistat 
        14.3.8    Phentermine 
        14.3.9    Methamphetamine 
        14.3.10    Tirzepatide  
    14.4    Japan Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action 
        14.4.1    Market Overview
        14.4.2    Centrally Acting Drugs 
        14.4.3    Peripherally Acting Drugs 
15    India Anti- Obesity Drugs Market
    15.1    India Anti-Obesity Drugs Market (2017-2032) Historical Value (2017-2023) 
    15.2    India Anti-Obesity Drugs Market (2017-2032) Forecast Value (2024-2032)
    15.3    India Anti-Obesity Drugs Market (2017-2032) by Drug Type
        15.3.1    Market Overview
        15.3.2    Semaglutide 
        15.3.3    Phentermine/topiramate 
        15.3.4    Naltrexone/bupropion 
        15.3.5    Liraglutide 
        15.3.6    Gelesis 100 
        15.3.7    Orlistat 
        15.3.8    Phentermine 
        15.3.9    Methamphetamine 
        15.3.10    Tirzepatide  
    15.4    India Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action 
        15.4.1    Market Overview
        15.4.2    Centrally Acting Drugs
        15.4.3    Peripherally Acting Drugs
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    Japan PMDA
        16.1.4    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication Year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by Year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    GlaxoSmithKline PLC 
        22.1.1    Financial Analysis
        22.1.2    Product Portfolio
        22.1.3    Demographic Reach and Achievements
        22.1.4    Mergers and Acquisitions
        22.1.5    Certifications
    22.2    Pfizer Inc. 
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisitions
        22.2.5    Certifications
    22.3    Novo Nordisk A/S 
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisitions
        22.3.5    Certifications
    22.4    Rhythm Pharmaceuticals 
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisitions
        22.4.5    Certifications
    22.5    KVK Tech Inc.
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisitions
        22.5.5    Certifications
    22.6    Currax Pharmaceuticals LLC 
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisitions
        22.6.5    Certifications
    22.7    CHEPLAPHARM Arzneimittel GmbH 
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisitions
        22.7.5    Certifications
    22.8    Vivus LLC 
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisitions
        22.8.5    Certifications
    22.9    Gelesis Holding Inc. 
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisitions
        22.9.5    Certifications
    22.10    Boehringer Ingelheim International GmbH 
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Mergers and Acquisitions
        22.10.5    Certifications
    22.11    Eli Lilly and Company 
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Mergers and Acquisitions
        22.11.5    Certifications
List not exhaustive
23    Anti-Obesity Drugs Treatment Drugs - Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Company Competitiveness Analysis (Additional Insight)
    25.1    Very Small Companies
    25.2    Small Companies
    25.3    Mid-Sized Companies
    25.4    Large Companies
    25.5    Very Large Companies
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.